Abiopharma

Q1 report for 2026

Net Asset Value(s)

Subject: Dividend Distribution Q1, 2026 - NIS 320,000,000

Infleqtion Expands UK Quantum Operations with New Oxford Innovation Centre and Manufacturing Hub

Navan Unlocks Savings for Travelers with First SAS NDC Direct Connect

Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million

KKR to Open New Office in Milan, Strengthening Long-Term Commitment to Italy

Navan Strengthens European Train Offering with Swedish Rail Integration

Investor Presentation - First Quarter of 2026

GPK Investors Have Opportunity to Lead Graphic Packaging Holding Company Securities Fraud Lawsuit with the Schall Law Firm